Cumberland announced the relaunch of Ethyol (amifostine) for Injection indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, and to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
Earlier this year, Cumberland entered into an exclusive agreement with Clinigen Group plc to commercialize Ethyol in the United States.
Ethyol, an organic thiophosphate cytoprotective agent, is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. The higher concentration of the thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites of cisplatin.
Ethyol for Injection is available as 500mg strength lyophilized powder per 10mL single-use vial in 3-count cartons.
For more information call (877) 484-2700 or visit Ethyol.com.